Health Care/Hospital

TriNetX Enhances its Ability to Federate Genomics Data Across its Global Network of Providers through the Acquisition of Key Assets of Zetta Genomics

TriNetX® will continue to support all existing Zetta Genomics customers utilizing the award-winning XetaBase® technology for research and patient care innovation CAMBRIDGE, Mass. and CAMBRIDGE, United Kingdom, April 7, 2026 /PRNewswire/ -- TriNetX, the world's leading federated health data netwo...

2026-04-07 19:32 105

Jin Medical International Ltd. Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

CHANGZHOU, China, April 7, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries and consolidated entities, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment, today announced that it has receive...

2026-04-07 19:00 462

Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development

-Fixed-dose combination of ASC30 and ASC39 (ASC30_39 FDC) tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in their respective monotherapies in a head-to-head study. The fixed dose combination had excellent oral bioavailability, drug exposure and a half-lif...

2026-04-07 19:00 487

Swiss Re Independently Validates 25:1 Return on Investment for Cancer Rehabilitation. Osara Health Delivered 91% of the Program Data.

Osara Health discloses its role as the primary cancer support provider in Swiss Re's independent Rehabilitation Watch 2025 report, which confirmed a 25:1 return on investment and the highest return-to-work rate of any condition at 71%. NEW YORK, April 7, 2026 /PRNewswire/ -- Swiss Re's Rehabilit...

2026-04-07 18:00 762

Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026

HONG KONG, April 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that, at the 2026 European Lung Cancer Congress (ELCC 2026), it reported updated results with a median follow-up of 21.45 months from a prospective, open-label, single-arm, multicenter Phase Ib/II ...

2026-04-07 11:28 567

Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement

MELBOURNE, Australia and INDIANAPOLIS, April 7, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1 2026). Q1 2026 Highlights * Q1 2026 unaudited ...

2026-04-07 06:57 297

NYSE Content Update: Join Us and 6,500+ Attendees at Marquee AI Event HumanX

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, April 6, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begin...

2026-04-06 21:11

Alar Breaks Key Barriers in Ketamine Therapy with Positive Phase 1 Results for Long-Acting Injectable ALA-3000 for Treatment-Resistant Depression

* By reducing dissociation and sedation risk, ALA-3000 may eliminate the ≥2-hour post-dose monitoring requirement, reducing clinic operating costs, improving patient throughput, and supporting a more cost-effective and reimbursement-aligned treatment model. TAICHUNG, April 6, 2026 /PRNewswire/ ...

2026-04-06 20:00

GC Biopharma Enhances IVIG Safety Profile with Advanced Prothrombotic Impurity Detection Technology

* Proprietary analytical method for precise Factor XI (FXI) measurement published in the Journal of Microbiology and Biotechnology * Novel IgG Blocker eliminates heterophilic antibody interference, ensuring clinical-grade purity and mitigating thromboembolic risks YONGIN, South Korea, April 6...

2026-04-06 14:28

The 93rd CMEF is set to open in Shanghai, as the world's largest medical device industry exhibition spotlights AI, robotics, and international cooperation

SHANGHAI, April 5, 2026 /PRNewswire/ -- The 93rd China International Medical Equipment Fair (CMEF) will be held from April 9 to 12 at the National Exhibition and Convention Center (NECC) in Shanghai. As the largest global medical device industry chain exhibition, this year's event under the theme...

2026-04-05 20:03 803

Ridgetech, Inc. Announces 1-for-150 Reverse Share Split

HANGZHOU, China, April 3, 2026 /PRNewswire/ -- Ridgetech, Inc., a Cayman Islands exempted company (the "Company") (Nasdaq: RDGT), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced that it expects to implement a 1-for-150 reverse share split on its ...

2026-04-04 00:00 3437

Fast-Acting Covalent Protein Drugs From a New High-Throughput Platform

HANGZHOU, China, April 3, 2026 /PRNewswire/ -- A team led by principal investigators Bobo Dang and Ting Zhou at Westlake University/Westlake Laboratory reported in Science a high-throughput platform for engineering fast-acting covalent protein therapeutics. Their work, titled "A high-throughput ...

2026-04-03 22:44 2108

Assembling Over 1,000 Human Genomes Affordably: New Method Powers Medicine's Future

HANGZHOU, China, April 3, 2026 /PRNewswire/ -- A research team led by Zhen-Xing Endowed Professor Jian Yang at the School of Life Sciences, Westlake University, together with collaborators, published their latest findings in Nature on April 1. The study innovatively developed a pangenome-informed...

2026-04-03 19:32 2192

Syneron Bio Announces Completion of $150 Million Series B Financing

BEIJING, April 3, 2026 /PRNewswire/ -- Syneron Bio, a leader in intelligent platform-driven macrocyclic peptide drug discovery, announced the successful closing of its Series B financing on March 31th. The round was led by an international life-science fund, with co-lead participation from Dechen...

2026-04-03 15:02 2150

VARON Marks Earth Hour 2026 with a Call for Sustainable Respiratory Care and Climate Action

NEW YORK, March 27, 2026 /PRNewswire/ -- In observance of Earth Hour 2026, VARON , a leading innovator in oxygen therapy solutions, reaffirms its commitment to advancing both respiratory health and environmental sustainability. As millions around ...

2026-04-03 13:40 1845

Korea's AI-Driven Healthcare Technologies Take Centre Stage at the upcoming WHX Bangkok 2026

BANGKOK, April 3, 2026 /PRNewswire/ -- WHX Bangkok 2026 organised by Informa Markets is set to be a landmark trade event for showcasing Korea's groundbreaking advancements in AI-driven healthcare and technology. Two leading Korean companies, Korea Body Information Co., Ltd. and maihub, will unvei...

2026-04-03 07:48 2279

TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions

Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record data Collaboration will expand Regeneron's world-leading genomic and proteomic EHR-linked database Growing database will continu...

2026-04-03 04:34 3143

Education Cannot Wait Launches Urgent Support to Protect Learning for Crisis-Affected Children in Lebanon

On her first day as ECW Director, Maysa Jalbout visits Lebanon to reaffirm ECW's commitment to the country's children, announce new emergency funding and mobilise urgent international support. BEIRUT, April 2, 2026 /PRNewswire/ -- Education Cannot Wait (ECW

2026-04-02 23:00 4159

ZEISS advances connected cataract and refractive workflows with new digital, AI and surgical innovations at ASCRS

ZEISS Medical Technology will discuss and showcase latest workflow technologies at ASCRS 2026: * Enhanced Cataract Workflow Efficiency and Patient Outcomes: MicroSurgical Technology irrigation/aspiration handpieces, tips and sleeves, now available for the DORC EVA NEXUSto offer increased surgi...

2026-04-02 21:00 3359

Earendil Labs Announces First Patient Dosed in a Phase IIa Trial of a Half-life Extended Anti-TL1A Antibody (HXN-1001) in Patients with Ulcerative Colitis

WILMINGTON, Del., April 2, 2026 /PRNewswire/ -- Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced the first patient has been dosed in a Phase IIa clinical trial of HXN-1001, a half-life extended anti-TL1A antibody, in patients with ulcerative c...

2026-04-02 19:00 2882
12345 ... 856